Global Non-Insulin Therapies for Diabetes Market Insights, Forecast to 2025

Table of Contents

1 Study Coverage

• 1.1 Non-Insulin Therapies for Diabetes Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Non-Insulin Therapies for Diabetes Market Size Growth Rate by Product
  • 1.4.2 Alpha-glucosidase Inhibitors
  • 1.4.3 Amylin Agonists
  • 1.4.4 Biguanides
  • 1.4.5 Dipeptidyl Peptidase-4 (DPP4) Inhibitors
  • 1.4.6 Glinides / Meglitinides
  • 1.4.7 GLP-1 Analogs / GLP-1 Agonists
  • 1.4.8 Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
  • 1.4.9 Sulfonylureas
  • 1.4.10 Thiazolidinediones
  • 1.4.11 Others
• 1.5 Market by End User
  • 1.5.1 Global Non-Insulin Therapies for Diabetes Market Size Growth Rate by End User
  • 1.5.2 Hospital Pharmacy
  • 1.5.3 Retail Pharmacies
  • 1.5.4 Online Pharmacy
  • 1.5.5 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Non-Insulin Therapies for Diabetes Market Size
  • 2.1.1 Global Non-Insulin Therapies for Diabetes Revenue 2014-2025
  • 2.1.2 Global Non-Insulin Therapies for Diabetes Sales 2014-2025
• 2.2 Non-Insulin Therapies for Diabetes Growth Rate by Regions
  • 2.2.1 Global Non-Insulin Therapies for Diabetes Sales by Regions
  • 2.2.2 Global Non-Insulin Therapies for Diabetes Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Non-Insulin Therapies for Diabetes Sales by Manufacturers
  • 3.1.1 Non-Insulin Therapies for Diabetes Sales by Manufacturers
  • 3.1.2 Non-Insulin Therapies for Diabetes Sales Market Share by Manufacturers
  • 3.1.3 Global Non-Insulin Therapies for Diabetes Market Concentration Ratio (CR5 and HHI)
• 3.2 Non-Insulin Therapies for Diabetes Revenue by Manufacturers
  • 3.2.1 Non-Insulin Therapies for Diabetes Revenue by Manufacturers (2014-2019)
  • 3.2.2 Non-Insulin Therapies for Diabetes Revenue Share by Manufacturers (2014-2019)
• 3.3 Non-Insulin Therapies for Diabetes Price by Manufacturers
• 3.4 Non-Insulin Therapies for Diabetes Manufacturing Base Distribution, Product Types
  • 3.4.1 Non-Insulin Therapies for Diabetes Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Non-Insulin Therapies for Diabetes Product Type
  • 3.4.3 Date of International Manufacturers Enter into Non-Insulin Therapies for Diabetes Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Non-Insulin Therapies for Diabetes Sales by Product
• 4.2 Global Non-Insulin Therapies for Diabetes Revenue by Product
• 4.3 Non-Insulin Therapies for Diabetes Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Non-Insulin Therapies for Diabetes Breakdown Data by End User

6 North America

• 6.1 North America Non-Insulin Therapies for Diabetes by Countries
  • 6.1.1 North America Non-Insulin Therapies for Diabetes Sales by Countries
  • 6.1.2 North America Non-Insulin Therapies for Diabetes Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Non-Insulin Therapies for Diabetes by Product
• 6.3 North America Non-Insulin Therapies for Diabetes by End User

7 Europe

• 7.1 Europe Non-Insulin Therapies for Diabetes by Countries
  • 7.1.1 Europe Non-Insulin Therapies for Diabetes Sales by Countries
  • 7.1.2 Europe Non-Insulin Therapies for Diabetes Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Non-Insulin Therapies for Diabetes by Product
• 7.3 Europe Non-Insulin Therapies for Diabetes by End User

8 Asia Pacific

• 8.1 Asia Pacific Non-Insulin Therapies for Diabetes by Countries
  • 8.1.1 Asia Pacific Non-Insulin Therapies for Diabetes Sales by Countries
  • 8.1.2 Asia Pacific Non-Insulin Therapies for Diabetes Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Non-Insulin Therapies for Diabetes by Product
• 8.3 Asia Pacific Non-Insulin Therapies for Diabetes by End User

9 Central & South America

• 9.1 Central & South America Non-Insulin Therapies for Diabetes by Countries
  • 9.1.1 Central & South America Non-Insulin Therapies for Diabetes Sales by Countries
  • 9.1.2 Central & South America Non-Insulin Therapies for Diabetes Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Non-Insulin Therapies for Diabetes by Product
• 9.3 Central & South America Non-Insulin Therapies for Diabetes by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Non-Insulin Therapies for Diabetes by Countries
  • 10.1.1 Middle East and Africa Non-Insulin Therapies for Diabetes Sales by Countries
  • 10.1.2 Middle East and Africa Non-Insulin Therapies for Diabetes Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Non-Insulin Therapies for Diabetes by Product
• 10.3 Middle East and Africa Non-Insulin Therapies for Diabetes by End User

11 Company Profiles

• 11.1 GSK
  • 11.1.1 GSK Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 GSK Non-Insulin Therapies for Diabetes Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 GSK Non-Insulin Therapies for Diabetes Products Offered
  • 11.1.5 GSK Recent Development
• 11.2 Eli Lilly
  • 11.2.1 Eli Lilly Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Eli Lilly Non-Insulin Therapies for Diabetes Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Eli Lilly Non-Insulin Therapies for Diabetes Products Offered
  • 11.2.5 Eli Lilly Recent Development
• 11.3 Sumitomo Dainippon Pharma
  • 11.3.1 Sumitomo Dainippon Pharma Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Products Offered
  • 11.3.5 Sumitomo Dainippon Pharma Recent Development
• 11.4 Intarcia Therapeutics
  • 11.4.1 Intarcia Therapeutics Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Products Offered
  • 11.4.5 Intarcia Therapeutics Recent Development
• 11.5 Servier
  • 11.5.1 Servier Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Servier Non-Insulin Therapies for Diabetes Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Servier Non-Insulin Therapies for Diabetes Products Offered
  • 11.5.5 Servier Recent Development
• 11.6 Jiangsu Hansoh Pharmaceutical
  • 11.6.1 Jiangsu Hansoh Pharmaceutical Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Products Offered
  • 11.6.5 Jiangsu Hansoh Pharmaceutical Recent Development
• 11.7 Novo Nordisk
  • 11.7.1 Novo Nordisk Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Novo Nordisk Non-Insulin Therapies for Diabetes Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Novo Nordisk Non-Insulin Therapies for Diabetes Products Offered
  • 11.7.5 Novo Nordisk Recent Development
• 11.8 Emisphere
  • 11.8.1 Emisphere Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Emisphere Non-Insulin Therapies for Diabetes Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Emisphere Non-Insulin Therapies for Diabetes Products Offered
  • 11.8.5 Emisphere Recent Development
• 11.9 Uni-Bio Science Group
  • 11.9.1 Uni-Bio Science Group Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 Uni-Bio Science Group Non-Insulin Therapies for Diabetes Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 Uni-Bio Science Group Non-Insulin Therapies for Diabetes Products Offered
  • 11.9.5 Uni-Bio Science Group Recent Development
• 11.10 Takeda
  • 11.10.1 Takeda Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 Takeda Non-Insulin Therapies for Diabetes Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 Takeda Non-Insulin Therapies for Diabetes Products Offered
  • 11.10.5 Takeda Recent Development
• 11.11 3SBio
• 11.12 Merck
• 11.13 Dong-A Pharmaceutical
• 11.14 Luye Pharma Group
• 11.15 Eurofarma
• 11.16 Geropharm
• 11.17 Alkem Labs
• 11.18 SatRx
• 11.19 Pfizer
• 11.20 Jiangsu Hengrui Medicine

12 Future Forecast

• 12.1 Non-Insulin Therapies for Diabetes Market Forecast by Regions
  • 12.1.1 Global Non-Insulin Therapies for Diabetes Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Non-Insulin Therapies for Diabetes Revenue Forecast by Regions 2019-2025
• 12.2 Non-Insulin Therapies for Diabetes Market Forecast by Product
  • 12.2.1 Global Non-Insulin Therapies for Diabetes Sales Forecast by Product 2019-2025
  • 12.2.2 Global Non-Insulin Therapies for Diabetes Revenue Forecast by Product 2019-2025
• 12.3 Non-Insulin Therapies for Diabetes Market Forecast by End User
• 12.4 North America Non-Insulin Therapies for Diabetes Forecast
• 12.5 Europe Non-Insulin Therapies for Diabetes Forecast
• 12.6 Asia Pacific Non-Insulin Therapies for Diabetes Forecast
• 12.7 Central & South America Non-Insulin Therapies for Diabetes Forecast
• 12.8 Middle East and Africa Non-Insulin Therapies for Diabetes Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Non-Insulin Therapies for Diabetes Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details